ITCCIR 2023 Program (Tentative)
Introduction
History of Heavy Ion Radiotherpy

Hirohiko Tsujii

QSTJ-CROS

Hiroshi Tsuji

QST

Cost effectiveness (Clinical 10)

Tatsuya Ohno

Gunma Univ.

1 Basic/Biophysics: Biology of charged particle therapy

Sumitaka Hasegawa

QST

2 Basic/Biophysics: Biological Aspect of FLASH Particle Therapy

Teruaki Konishi

QST

3 Translational 1: Anti-tumor immunity induced by HIRT

Tsuguhide Takeshima

QST

Sei Sai

QST

5 Risk control: Radiation and Risk of Cancer

Tatsuhiko Imaoka

QST

6 Radiopharmaceutical Therapy

Atsushi Tsuji

QST7 Precision CIRT

Takahiro Oike

Gunma Univ.

8 Normal tissue effects

Yukari Yoshida

Gunma Univ.

1 Accelerator for CIRT and Quantum Scalpel

Yoshiyuki Iwata

QST

2 Dosimetry of Carbon-ion Beam

Makoto Sakama

QST

3 Beam Delivery, QA and Audit

Hideyuki Mizuno

QST

4 Biological models in CiRTTaku Inaniwa

QST

5 Treatment planning and range uncertainty in carbon-ion radiotherapy

Nobuyuki Kanematsu

QST

6 Facility commissioning at OSAKA HIMAK

Toshiro Tsubouchi

OSAKA HIMAK

7 Facility commissioning at Yamagata Univ.

Hikaru Souda

8 What particle therapy can Learn from High-Tec X-ray Therapy

Arnold Pompos

9 Dose constrains in HN

Maria Varnava

Gunma Univ.

10 Motion management & Adaptive therapy

Makoto Sakai

Gunma Univ.

1 Head & Neck Cancer

Masashi Koto

QST

2 Pancreas Cancer

Makoto Shinoto

QST

3 Bone & Soft tissue Sarcoma

Reiko Imai

QST

4 Liver Cancer

Kei Shibuya

Gunma Univ.

5 Gynecological Cancer

Kazutoshi Murata

QST

6 Eye Cancer

Masaru Wakatsuki

QST

7 Urological Cancer

Hitoshi Ishikawa

QSTBiology

4Translational 2: Overview of the State-of-the-Art Bench to Bedside Research inCarbon-ion Radiobiology

Physics

Yamagata University East
Japan Heavy Ion Center
UT Southwestern MedicalCenterClinical8 Locally recurrent Colorectal Cancer

Hirotoshi Takiyama

QST

9 Lung Cancer

Mio Nakajima

QST

10 Cost effectivenessTatsuya Ohno

Gunma Univ.

Kana Yamazaki

QSTRiwa Kishimoto

QST

Hideyuki Sakurai

Tsukuba Univ.

Diagnosis
1 Diagnostic PET/SPECT imaging for CIRT2

ACR Reporting and Data System (RADS) Essential for treatment of lung, liver andprostate cancer

Topics1History of particle beam therapy in Japan fromthe perspective of national healthpolicy2 Overview of BNCT and Current status of Accelerated-based BNCT

Yoshihiro Takai

3 Risk communication

Tomoaki Tamaki

Southern Tohoku BNCTResearch Center
Fukushima MedicalUniversity

Tour & Case Study
1 Tour (QST)

Toshiyuki Shirai

QST

2 Case Study 1 HN Cancer

Atsushi Musha

Gunma Univ.

3 Case Study 2 Lung Cancer with IP

Nobuteru Kubo

Gunma Univ.

4 Case Study 3 Locally advanced Liver Cancer

Kei Shibuya

Gunma Univ.

1 Toshiba ESS

Mizue Sekine

Toshiba ESS

2 Sumitomo

Hideki Nonaka

Sumitomo

3 Hitachi

Nozomi Kawasaki

Hitachi4 B dot Medical

Naoya Saotome

B dot Medical

5 Anzai

Kenichi Matsuoka

Anzai

6 Cosylab

Ian Norton

Cosylab

7 RaySearchLars Glimelius

RaySearch

8 Alfresa Pharma

Yasuo WadaAlfresa Pharma

1 East Japan Heavy Ion Center, Faculty of Medicine, Yamagata University

Takeo Iwai

Yamagata Univ.

2 Osaka Heavy Ion Therapy Center : OSAKA HIMAK

Osamu Suzuki

OSAKA HIMAK

5 Tour (GUNMA Univ.)
Vender presentation

Facility Introduction

Heavy Ion Therapy Center & Heavy Ion Therapy Research Institute3 Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University
Health System

Ik Jae LEE

Yonsei University HealthSystem*) QST : National Institutes for Quantum Science and Technology